Garcia 2012.
Methods | Randomised parallel‐group placebo‐controlled study | |
Participants | Reported as 41 participants with severe non‐atopic asthma uncontrolled despite daily high‐dose inhaled corticosteroids (with or without maintenance oral corticosteroids) plus a long‐acting beta2‐agonist | |
Interventions | Randomly assigned to receive omalizumab or placebo in a 1:1 ratio 16‐Week study |
|
Outcomes | Reported as the following: The primary endpoint was change in expression of high‐affinity IgE receptor FceRI on blood basophils and plasmacytoid dendritic cells (pDC2) after 16 weeks. Impact on lung function and clinical parameters was also assessed | |
Notes | Funded by Novartis Pharma SAS | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Details not provided (conference abstract) |
Allocation concealment (selection bias) | Unclear risk | Details not provided (conference abstract) |
Blinding (performance bias and detection bias) All outcomes | Unclear risk | Details not provided (conference abstract) |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Details not provided (conference abstract) |
Selective reporting (reporting bias) | Unclear risk | Not possible to assess from conference abstract |